ADVA launches industry’s most compact timing solution for digital power substations
11.3.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-P substation grandmaster, an ultra-compact synchronization solution specifically designed for the digital transformation of power utility networks. The OSA 5405-P delivers the precise and reliable timing that utilities need to leverage new smart grid applications, including intelligent power generation, distribution and control systems. The solution protects mission-critical infrastructure from the risk of outages caused by loss of timing from satellite signals by combining GNSS receivers with accurate PTP grandmaster clocks and network-delivered timing. Available with rack, DIN rail and wall mounting options, the OSA 5405-P also reduces cost and complexity in synchronization networks. What’s more, by supporting both legacy and new timing technologies, the solution empowers utility networks to smoothly and cost-effectively transition to next-generation synchronization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005049/en/
ADVA’s OSA 5405-P is a key building block for power network operators seeking to develop smart grid applications (Graphic: Business Wire)
“The utility network landscape is changing. With the move to distributed power generation and the digital transformation of substations, utilities face a new set of challenges and opportunities. To succeed, all processes must be tightly synchronized and a new level of accurate, robust timing is required. Our OSA 5405-P addresses these exact needs and offers power network operators a simple and affordable route from legacy synchronization to fully protected and assured PTP timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Now utility networks can leverage a solution tailored to their precise needs that’s easy to install anywhere. And with our sophisticated Ensemble Controller and Sync Director, synchronization is easy to manage and operate.”
The OSA 5405-P offers power network operators a risk-free way to migrate their existing timing infrastructure to the accurate and robust PTP timing needed for new automated technologies and smart grid applications. With network-based synchronization backing up timing from GNSS, the OSA 5405-P removes vulnerability to loss of satellite signals. It supports multiple PTP profiles, including the Power Profile, and features NTP as well as IRIG-B interfaces for precise time synchronization of all power system devices. Its Syncjack™ capabilities also deliver accurate, real-time monitoring of synchronization quality. The OSA 5405-P is the ultimate power utility synchronization solution where cost-efficiency and small footprint are key. With rack and DIN rail mounting options, it’s extremely versatile to deploy. Ideal for secondary substations, it can also complement the OSA 5422-IRIG solution in primary substations. The OSA 5405-P also utilizes in-service sync probing and assurance as well as innovative GNSS assurance capabilities.
“Smart grids need intelligent timing. That’s what our OSA 5405-P offers. It brings assured and protected synchronization to the edge of the power network in an extremely cost-efficient way. Now operators can rely on their infrastructure delivering the robust and accurate timing needed for new secondary substation and protection relay technologies,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “The compact and environmentally friendly design of our solution will be especially valuable as utility networks migrate to packet-based timing. The OSA 5405-P distributes accurate timing with the smallest size and power footprint on the market. That means major savings on rack space and a significant reduction in complexity.”
Further details on the OSA 5405-P are available in these slides: https://adva.li/osa-5405-p-slides.
A supporting solution brief can be downloaded here: https://adva.li/osa-5405-p-solution-brief.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005049/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
